Radioactive drug for advanced neuroendocrine and other cancers
Treatments studied
Part of Brain & nervous system, Cancer, Ear, nose & throat, Kidney & urinary, Mouth & dental, Women’s health & pregnancy clinical trials.
This trial tests a new radioactive drug, [212Pb]VMT-Alpha-NET, that targets a protein on certain cancer cells. It is for people with specific types of advanced cancers that have gotten worse and are not responding to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have one of these cancers: gastrointestinal neuroendocrine tumors, pheochromocytoma/paraganglioma, small cell lung cancer, kidney cancer, or head and neck cancer.
- Your cancer has spread to other parts of the body or cannot be removed with surgery.
- You have received certain prior treatments depending on your cancer type (for example, at least one chemotherapy or immunotherapy for small cell lung cancer).
- You have not had a previous treatment with a radioactive drug that targets cancer cells.
- Your cancer has shown signs of growth or worsening symptoms in the last 3 years.
- Your tumors have a specific protein called somatostatin receptors, found on a special scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new radioactive drug, [212Pb]VMT-alpha-NET, that targets a receptor found on some tumor cells. It is for people with certain gut or adrenal gland tumors that have already been treated with a similar therapy but are still growing.
This trial tests a radioactive drug called 211At-MABG for people with advanced neuroendocrine cancers that have stopped responding to other treatments. The drug targets cancer cells that show up on a special MIBG scan, delivering radiation directly to the tumor.
This trial tests a targeted form of radiation made to stick to specific “somatostatin receptor” markers on tumors. It is designed for people with advanced, receptor-positive neuroendocrine tumors or meningioma who may have had prior treatments and need more options.
This Phase 3 study tests whether a targeted radiation treatment approach (using a special “PRRT” scan-guided method) works better to control advanced neuroendocrine tumors. It’s designed for tumors that show strong targeting on a specific PET scan and that are growing despite prior treatment (with some limits).
This trial tests a radioactive drug called Lutathera for people with neuroendocrine tumors that are not in the stomach or intestines and can't be removed by surgery. The drug targets a specific receptor on the tumor cells to deliver radiation directly, which may help slow or shrink the cancer.
This phase 3 trial tests a radioactive drug (177Lu-DOTATATE) against a long-acting medication (Octreotide LAR) for people with advanced neuroendocrine tumors (NETs) that have grown despite standard treatment. The study aims to see which treatment works better and is safer.
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.